# Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

> **NCT03028103** · PHASE1 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Lymphoma
- Mantle Cell Lymphoma
- Advanced Solid Tumor
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Fluconazole
- **DRUG:** Omeprazole
- **DRUG:** Repaglinide

## Key facts

- **NCT ID:** NCT03028103
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-11-29
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03028103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03028103, "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03028103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*